TABLE 1.
Patient and Tumor Characteristics
| Total n = 274 | FLX n = 183 | GNP n = 91 | P | |
|---|---|---|---|---|
| Age, median (IQR) | 64 (57.3–69) | 62 (56.5–68) | 66 (61.8–72) | <0.001* |
| Female, n (%) | 148 (54) | 102 (55.7) | 46 (50.5) | 0.442 |
| BMI, kg/m2 (IQR) | 24.9 (22.3–28.9) | 24.9 (22.2–28.6) | 25.4 (22.4–29.1) | 0.38 |
| Race/Ethnicity | ||||
| White non-Hispanic | 213 (77.7) | 137 (74.9) | 76 (83.5) | |
| African-American | 36 (13.1) | 26 (14.2) | 10 (11) | |
| Hispanic | 17 (6.2) | 14 (7.7) | 3 (3.3) | 0.226 |
| Asian | 3 (1.1) | 1 (0.5) | 2 (2.2) | |
| Unknown | 5 (1.9) | 5 (2.7) | 0 | |
| ASA | ||||
| 2 | 66 (24) | 48 (26.2) | 18 (19.8) | |
| 3 | 178 (65) | 111 (60.7) | 67 (73.6) | 0.293 |
| 4 | 4 (1.5) | 3 (1.6) | 1 (1.1) | |
| Unknown | 26 (9.5) | 21 (11.5) | 5 (5.5) | |
| ECOG performance status | ||||
| 0 | 135 (49.2) | 82 (44.8) | 53 (58.2) | |
| 1 | 85 (31) | 63 (34.4) | 22 (24.2) | |
| 2 | 22 (8) | 16 (8.7) | 6 (6.6) | 0.106 |
| 3 | 5 (1.9) | 2 (1.1) | 3 (3.3) | |
| Unknown | 27 (9.9) | 20 (10.9) | 7 (7.7) | |
| Tumor Location | ||||
| Head/neck | 228 (83.2) | 152 (83.1) | 76 (83.5) | |
| Body | 24 (8.8) | 15 (8.2) | 9 (9.9) | 0.278 |
| Tail | 15 (5.4) | 11 (6) | 4 (4.5) | |
| Unknown | 7 (2.6) | 5 (2.7) | 2 (2.2) | |
| Bile duct dilation, (head/neck; n = 228) | 204 (89.4) | 132 (86.8) | 72 (94.7) | 0.165 |
| Preoperative stenting (head/neck; n = 228) | 182 (79.8) | 109 (71.7) | 73 (96) | <0.001* |
| Radiological classification at diagnosis | ||||
| Resectable | 61 (22.3) | 40 (21.9) | 21 (23.1) | |
| BRPC | 127 (46.4) | 79 (43.2) | 48 (52.7) | |
| LAPC | 70 (25.5) | 56 (30.6) | 14 (15.4) | 0.034* |
| Unknown | 16 (5.8) | 8 (4.4) | 8 (8.8) |
ASA indicates American Society of Anesthesiologists; BMI, body mass index; BRPC, borderline resectable pancreatic cancer; ECOG, Eastern Cooperative Oncology Group; FLX, FOLFIRINOX; GNP, gemcitabine/nab-paclitaxel; IQR, interquartile range; LAPC, locally advanced pancreatic cancer,
*
Statistically significant.